INSIGHTS

INSIGHTS

Explore relevant life science news & events, helping drive industry research forward to improve human health.

Refine Insights By:

Biologics Development Survival Checklist: Helping Great Teams Discover Successful Biotherapeutics
Blog Posts

Biologics Development Survival Checklist: Helping Great Teams Discover Successful Biotherapeutics

Explore a practical biologics development checklist covering regulatory planning, safety, specificity, manufacturability, logistics, and team resilience.

Watch How to Run a Bioassay Video
Webinars

Watch How to Run a Bioassay Video

Easy-to-Run, Robust Bioassays! Bioassays are ready-to-use, cell-based assays for multiple mechanisms of action. They are sensitive and reproducible assays that provide quantitative results and have simple homogeneous (no wash) protocols. Bioassays are target-based and qualified for your lead optimization to QC lot release programs.

SPS 2026 Annual Meeting
Events

SPS 2026 Annual Meeting

Visit us at Booth # 12

Eurofins Discovery Awards its Top Innovators of the Year
News

Eurofins Discovery Awards its Top Innovators of the Year

Eurofins Discovery proudly celebrates its 2025 innovators, recognizing outstanding team members and teams for their exceptional contributions to scientific advancement and business innovation.

Eurofins Discovery Announces Sponsorship of Bayer Co.Lab Cambridge in Support of Emerging Biotech Innovation
News

Eurofins Discovery Announces Sponsorship of Bayer Co.Lab Cambridge in Support of Emerging Biotech Innovation

Eurofins Discovery, a leading provider of products and services that support Pharma and Biotech to advance drug discovery and development, today announced a sponsorship agreement with Bayer Co.Lab Cambridge, Bayer’s premier life sciences incubator located in Kendall Square, Massachusetts.

Advancing ADC Development: End-to-End Solutions from Design to Characterization
Blog Posts

Advancing ADC Development: End-to-End Solutions from Design to Characterization

Since the first FDA approval in 2000, the antibody-drug conjugate (ADC) pipeline has grown extensively, with more than 100 ADCs in active clinical trials and many more in preclinical development.